^
Association details:
| Biomarker: | HR positive + BRCA2 mutation + PALB2 mutation |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug Class: | CDK4 inhibitor + CDK6 inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
Impact of pathogenic germline BRCA1/2 and PALB2 mutations and tumor aneuploidy in patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors.
Published date:
05/25/2023
Excerpt:
Clinical and molecular data from a single institution cohort of CDK4/6i-treated HR+/HER2- mBC pts were analyzed….Cox regression showed a strong negative impact of gBRCA1/2-PALB2 on PFS (HR 4.0 CI 2.0–7.9) and OS (HR 3.5 CI 1.6–7.7)...Pathogenic gBRCA1/2-PALB2 and higher aneuploidy were associated with shorter survival.
DOI:
10.1200/JCO.2023.41.16_suppl.1075
